Stephen G. Schwartz
About
In The Last Decade
Stephen G. Schwartz
149 papers receiving 3.1k citations
Peers
Comparison fields: 5 of 131
- Ophthalmology 2.4k
- Radiology, Nuclear Medicine and Imaging 1.5k
- Molecular Biology 601
- Neurology 330
- Cognitive Neuroscience 277
Countries citing papers authored by Stephen G. Schwartz
This map shows the geographic impact of Stephen G. Schwartz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen G. Schwartz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen G. Schwartz more than expected).
Fields of papers citing papers by Stephen G. Schwartz
This network shows the impact of papers produced by Stephen G. Schwartz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen G. Schwartz. The network helps show where Stephen G. Schwartz may publish in the future.
Co-authorship network of co-authors of Stephen G. Schwartz
This figure shows the co-authorship network connecting the top 25 collaborators of Stephen G. Schwartz. A scholar is included among the top collaborators of Stephen G. Schwartz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen G. Schwartz. Stephen G. Schwartz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 2 | |
| 4 | 5 | |
| 5 | 0 | |
| 6 | 0 | |
| 7 | 4 | |
| 8 | Retinal pigment epithelium (RPE) pigmentary changes are associated with progression from early to advanced age-related macular degeneration (AMD) independent of CFH and ARMS2 risk genotypes. | 2 |
| 9 | 10 | |
| 10 | 1 | |
| 11 | Current Endophthalmitis Incidence Rates After Intravitreal Anti-VEGF Injections and Outcomes of Treatment | 1 |
| 12 | 31 | |
| 13 | 40 | |
| 14 | Coding Variants In The ARMS2 Gene And The Risk Of Age-related Macular Degeneration | 2 |
| 15 | Pharmacogenomics Of Steroid Response In The Eye | 1 |
| 16 | The Role of Genetics and Smoking in Response to Anti-VEGF Therapy for Wet AMD | 2 |
| 17 | Endophthalmitis After Intravitreal Anti-Vascular Endothelial Growth Factor Antagonists: A Six-Year Experience at a University Referral Center | 7 |
| 18 | Patient-Reported Visual Function Over 24 Months in Predominantly Classic Neovascular AMD: Results From ANCHOR, a Phase III Trial of Ranibizumab and Verteporfin PDT | 3 |
| 19 | 3 | |
| 20 | Risk Factors for Age-Related Macular Degeneration | 4 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.